Lenvima (lenvatinib)
pCPA File Number:
22016
Negotiation Status:
Active Negotiation
Indication(s):
In combination with pembrolizumab (Keytruda), for the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation
Sponsor/Manufacturer:
Eisai Limited
CADTH Project Number:
PC0288
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable